Psilocybin

赛洛西宾

Report date: 2026/05/23 20:00:57

Base Information

Drug NamePsilocybin
Drug Alias NamePsilocybineTRP-8802TRP-8803TRP-8804TRYP-0082 +[7
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1a (5-HT1a) receptor agonistsSerotonin 2a (5-HT2a) receptor agonists
TargetsSerotonin 2a (5-HT2a) receptorSerotonin 1a (5-HT1a) receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Bipolar II DisorderHemorrhagic Stroke +[83
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[19
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesTRYP Therapeutics Inc
China Registration ClassN/A

Develop Information

Active IndicationsCoronavirus Disease 2019 (COVID-19)Bipolar II DisorderHemorrhagic Stroke +[73
Inactive IndicationsMental DisordersSuicidal IdeationCocaine-Related Disorders +[10

Other Information

ATC CodeN/A